Technical Service
Develop and produce rare proteins and traditional difficult to produce proteins, achieving high-end "intelligent manufacturing" of drug proteins
Cooperative Development of Macromolecular Protein Drugs
Cell-free protein expression
It has become a popular tool in many fields of biology, ranging from synthetic biology to industrial biomanufacturing.
Compared with traditional intracellular protein expression methods,Cell-free protein expressionAble to carry outQuick,Low costProtein production, owing to its open reaction environment and the absence of cellular structures and physiological constraints, can readily carry out all intracellular metabolic and synthetic processes within conventional reaction vessels, thereby exhibiting exceptional versatility and flexibility. This facilitates efficient substrate processing, precise online reaction monitoring, and direct process optimization.
Leveraging the Perotin Bio technical team’s extensive expertise in DNA synthesis and molecular cloning, combined with our versatile and highly efficient…Cell-free protein expression platform, for the customerCustom Projector professional applications offer unique andComprehensive solution.
Proteins and protein therapeutics that are difficult to express
| Name | Function, use | Traditional Difficulties | Perotin expression |
| Onconase | Phase III clinical drug for mesocortical carcinoma | Cytotoxicity | Highly expressive, mass-producible |
| Cyanovirin-N | Anti-HIV drug candidate with difficult cellular expression | Inactive | |
| Botulinum toxin Hc segment | C segment antigen of botulinum toxin heavy chain | Low yield | |
| Heme oxygenase | Cytoprotective effect against apoptosis | Low yield | |
| Interleukin 4 | Allergic and autoimmune diseases | Low yield | |
| Interferon 2 | Anti-inflammatory, anti-viral, anti-tumour | Low yield | |
| Calreticulin | Tumour markers | Low yield | |
| Snake venom serine protease | Cardiovascular diseases | Dependency Extraction | |
| Cysteine asparaginase 1 | Apoptosis-related | Low yield | |
| Glycerol 3-phosphate dehydrogenase | Cancer Targets | Cytotoxicity |
Case Showcase
Ustatin is a trypsin inhibitor extracted from adult male urine, containing 143 amino acids, six pairs of disulfide bonds and two post-translational modifications, two Kunitz structural domains, respectively, all of which inhibit proteases and form multivalent enzyme inhibitory activity. Clinically, it is mainly used in the field of acute and critical illness, pancreatitis and perioperative field, with the effect of blocking SIRS, protecting organs, inhibiting enzymes and anti-inflammation, effectively treating pancreatitis, relieving emergency and improving the success rate of surgery. Ustatin was firstly researched and developed by Ikeda Pharmaceutical Company in Japan, and domestic enterprise Tianpu Biochemical successfully copied it in 1999 and achieved import substitution. At present, in addition to Japan and China, the preparation of ustekin is only listed for sale in South Korea, India and a few other Asian countries. However, although the drug has been on the market for many years, the production process has been dependent on urine extraction. It is very difficult to carry out large-scale urine collection in foreign countries. Currently, almost all raw materials for the preparation of human-derived urinary protein drugs come from China, but with the advancement of urbanisation, rising labour costs and improved environmental hygiene requirements in China, the use of traditional processes to produce crude human-derived proteins is becoming more and more restricted, with inherent weaknesses such as large source dependence, long transport distances, and low production efficiencies. According to the existing reports, although there are attempts to express ustekin human protein products by recombination, such as the recombinant expression and in vitro pharmacodynamics of ustekin in Pichia yeast cells and soybean hairy root, and the fusion expression of human serum albumin and ustekin using Chinese hamster ovary cells, etc., there are no successful cases of commercial recombinant expression production yet.
Market Forecast and Global Market Status of Human Urinary Trypsin Inhibitor (UTI) and Ulinastatin
Perotin Bio offers a potential solution for the non-extraction-dependent production of recombinant ustustatin (rUTI) through its own PLD cell-free protein expression platform. The use of cell-free protein expression technology for the production of rUTI, a protein drug that is extraction-dependent and difficult to obtain through conventional cellular fermentation methods, allows for simple, rapid and large quantities of the target protein raw material to be obtained without the restriction of the raw material source, with a short process flow and easy purification. According to the activity test method provided by the Chinese Pharmacopoeia, the activity of rUTI protein output from the PLD cell-free protein expression platform was >3500 U/mg, which meets the activity requirements of the Pharmacopoeia.
UTI Protein Modelling
rUTI Expressed Protein Strips
Linear amplification of cell-free protein production
Perotin rUTI is consistent with on-sale urine-derived UTI activity
Leave a Message Online
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
